[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100582443":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":25,"locations":30,"responsibleParty":53,"collaborators":25,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":61,"acronym":25,"eligibilityCriteria":62,"healthyVolunteers":59,"sex":63,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":25,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":25,"overallStatus":33,"whyStopped":25,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Tanta University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Control group","ACTIVE_COMPARATOR","Patients will receive the standard conventional therapy in addition to placebo for 3 months.",[13],"Other: Physical activity, walking, and calorie restriction",{"label":15,"type":10,"description":16,"interventionNames":17},"Carbocistiene group","Patients will be given the standard conventional therapy plus carbocistiene 375 mg two times daily.",[18,13],"Drug: Carbocysteine 375 MG",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Carbocysteine 375 MG","Carbocysteine is a muco-active drug with free radical scavenging and anti-inflammatory properties. It is actually approved for clinical use as adjunctive therapy of respiratory tract disorders",[15],null,{"type":6,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Physical activity, walking, and calorie restriction","• The standard conventional therapy in both groups included regular exercise in the form of any physical activity as walking, cycling, etc. for 30-45 minutes minimum 5 days per week in addition to calorie restriction in overweight and obese patients",[15,9],[31],{"facility":32,"status":33,"city":34,"state":25,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Tanta Unuversity","RECRUITING","Tanta","31527","Egypt","EG",{"type":39,"coordinates":40},"Point",[41,42],31.00192,30.78847,{"lat":42,"lon":41},[45,50],{"name":46,"role":47,"phone":48,"phoneExt":25,"email":49},"Mostafa M I Bahaa, PhD","CONTACT","0201025538337","mbahaa@horus.edu.eg",{"name":51,"role":52,"phone":25,"phoneExt":25,"email":25},"Mostafa M Bahaa, PhD","SUB_INVESTIGATOR",{"type":54,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Mostafa Bahaa","Lecturer","100582443","phase-2-evaluating-the-safety-and-efficacy-of-carbocisteine-in-the-treatment-of-nonalcoholic-fatty-liver-disease-patients-100582443",false,"NCT06863376","Evaluating the Safety and Efficacy of Carbocisteine in the Treatment of Nonalcoholic Fatty Liver Disease Patients","Inclusion Criteria:\n\n* Either male or female adult patients (\\>18 years) with fatty liver diagnosis by using upper abdominal ultrasound echography\n\nExclusion Criteria:\n\n* Pregnant and\u002For lactating women\n* Excessive alcohol use (defined as an average alcohol intake \\> 30 g per day in men and \\> 20 g per day in women)\n* Other etiology of chronic liver diseases such as viral hepatitis, drug-induced hepatitis, autoimmune hepatitis.\n* patients suffering from chronic kidney disease, and hyper\u002Fhypoparathyroidism\n* Hypersensitivity to carbocistiene.","ALL","18 Years","65 Years",{"count":67,"type":68},46,"ESTIMATED","INTERVENTIONAL",[71],"PHASE2","Nonalcoholic fatty liver disease (NAFLD) is a global public health concern, and the leading cause of chronic liver disease, especially in developed countries. NAFLD is characterized by lipid accumulation in the liver not attributed to other causes. Lifestyle interventions, including dietary modification and exercise, remain the cornerstone of NAFLD treatment. Pharmacological treatments aimed primarily at improving liver disease should generally be limited to those with biopsy-proven NASH and fibrosis.",[74],"Non-Alcoholic Fatty Liver Disease","2026-05-01",{"date":77,"type":78},"2026-05-04","ACTUAL",{"date":80,"type":78},"2025-03-01",{"date":82,"type":68},"2027-04-20",{"name":5,"class":6},1]